Tag: Abbott And Galapagos enter into global collaboration to develop inhibitor fot anti-immune diseases

Abbott and Galapagos enter into global collaboration to develop inhibitor for anti-immune diseases

March 2, 2012

ABBOTT Laboratories recently announced that the company and Galapagos, a mid-size biotechnology company, have entered into a global collaboration to develop and commercialize an oral, next-generation JAK1 inhibitor in Phase II development with the potential to treat multiple autoimmune diseases. Under the terms of the agreement, Abbott will make an initial upfront payment of $150 […]

Continue Reading